Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 2
2012 3
2013 2
2014 8
2015 6
2016 3
2017 1
2018 3
2019 3
2020 2
2021 7
2022 6
2023 6
2024 4
2025 18
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean calogero ietro (1,588 results)?
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.
Vetro C, Azzali I, Petracci E, Papayannidis C, Eleuteri E, Palumbo FE, Federico V, Fracchiolla N, Zappasodi P, Martelli MP, Giannini MB, Brunetti L, Palmieri R, Nanni J, Simonetti G, Guolo F, Minetto P, Maurillo L, Gigli F, Billio A, Todisco E, Martinelli G, Marconi G. Vetro C, et al. Hematol Oncol. 2026 Jan;44(1):e70169. doi: 10.1002/hon.70169. Hematol Oncol. 2026. PMID: 41527965 Free PMC article.
Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database.
Scala A, Trunfio TA, Pennisi C, Lombardo GE, Micale V, Martino SD, Fiorenza G, Graziano ACE, Briglia M, Allia F, Giurdanella G, Malaguarnera R, Battaglia R, Gozzo C, Palumbo FE, Vetro C, Improta G, Toro MD, Drago F, Romano GL, Gozzo L. Scala A, et al. Among authors: vetro c. Pharmaceuticals (Basel). 2025 Dec 16;18(12):1895. doi: 10.3390/ph18121895. Pharmaceuticals (Basel). 2025. PMID: 41471384 Free PMC article.
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.
Palmieri R, Guolo F, Fianchi L, Ferrara F, Minetto P, Martelli MP, Riva C, Chiusolo P, Rondoni M, Capria S, Minotti C, Pilo F, Perrone S, Corbingi A, Grimaldi F, De Luca G, Fili C, Alati C, Mannelli F, Lessi F, Marchesi F, Brunetti L, Capelli D, Piccioni AL, Vetro C, Palumbo FE, Mazzone C, Sperotto A, Luzi G, Dargenio M, Mariani S, Cerrano M, Mulè A, Di Veroli A, Meddi E, Moretti F, Papayannidis C, Isidori A, Ferrari A, Galimberti S, Cilloni D, Breccia M, Lanza F, Gottardi M, Cairoli R, Candoni A, Pagano L, Todisco E, Lemoli RM, Venditti A, Buccisano F. Palmieri R, et al. Among authors: vetro c. Blood Adv. 2025 Dec 4:bloodadvances.2025017089. doi: 10.1182/bloodadvances.2025017089. Online ahead of print. Blood Adv. 2025. PMID: 41346286
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.
Vetro C, Garibaldi B, Grimaldi F, Chiusolo P, Filì C, Riva C, Cardinali V, Franciosa M, Pilo F, Palmieri R, Esposito L, Menotti D, Perrone S, Mulè A, Alati C, Vigna E, Dargenio M, De Luca G, Sperotto A, Tanasi I, Papayannidis C, Molica M, Minetto P, Battipaglia G, Memoli M, Salutari P, Brunetti L, Todisco E, Lotesoriere I, Isidori A, Palumbo GA, Annunziata M, Gottardi M, Gentile M, Martelli MP, Capelli D, Martino M, Rossi M, Ferrara F, Venditti A, Romani C, Galimberti S, Candoni A, Fianchi L, Pagano L, Marconi G, Lemoli RM, Di Raimondo F, Billio A, Palumbo FE, Pane F, Duminuco A, Guolo F. Vetro C, et al. Blood Cancer J. 2025 Dec 4;15(1):213. doi: 10.1038/s41408-025-01431-5. Blood Cancer J. 2025. PMID: 41345216 Free PMC article. No abstract available.
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.
Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM, Calmet FV, Campbell V, Cetin D, Cimino G, Ciotti G, Corbingi A, De Fazio L, Erol HA, Federico V, Gil C, Mutlu YG, Malcorra AB, Mariani S, Mazzone C, Mulè A, Musuraca G, Khan A, Norata M, O'Nions J, Palumbo FE, Papayannidis C, Piccioni AL, Rubio MTO, Sanchez-Tovar J, Serin I, Serrao A, Sevindik OG, Sucato G, Urbano MA, Vetro C, Vives S, Rossi M, Martelli MP, Montesinos P, Othman J, Perrone S. Molica M, et al. Among authors: vetro c. Am J Hematol. 2026 Jan;101(1):89-96. doi: 10.1002/ajh.70142. Epub 2025 Nov 22. Am J Hematol. 2026. PMID: 41273181 Free PMC article.
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.
Petracci E, Pavesi F, Castagna L, Zappasodi P, Papayannidis C, Vetro C, Federico V, Cignetti A, Borlenghi E, Fracchiolla N, Facchini L, Maurillo L, Audisio E, Bernardi M, Ferrara F, Lanza F, Selleri C, Manfra I, Cerchione C, Nanni J, Romagnoli AD, Marconi G, Zingaretti C, Lotesoriere I, Gigli F, Martinelli G, Todisco E. Petracci E, et al. Among authors: vetro c. Br J Haematol. 2025 Nov 12. doi: 10.1111/bjh.70248. Online ahead of print. Br J Haematol. 2025. PMID: 41224500 No abstract available.
70 results